445.21
1.04%
+4.57
After Hours:
445.21
Vertex Pharmaceuticals, Inc. stock is currently priced at $445.21, with a 24-hour trading volume of 1.38M.
It has seen a +1.04% increased in the last 24 hours and a +13.26% rose in the past month.
The chart indicates a potential bullish trend, as the stock is above the $438.2 pivot point. If it approaches the $447.6 resistance level, significant changes may occur.
Previous Close:
$440.64
Open:
$442
24h Volume:
1.38M
Market Cap:
$114.89B
Revenue:
$10.19B
Net Income/Loss:
$4.02B
P/E Ratio:
33.40
EPS:
13.33
Net Cash Flow:
$3.48B
1W Performance:
+5.31%
1M Performance:
+13.26%
6M Performance:
+27.02%
1Y Performance:
+30.48%
Vertex Pharmaceuticals, Inc. Stock (VRTX) Company Profile
Name
Vertex Pharmaceuticals, Inc.
Sector
Industry
Phone
617-341-6100
Address
50 Northern Avenue, Boston, MA
Vertex Pharmaceuticals, Inc. Stock (VRTX) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Feb-15-24 | Initiated | Wolfe Research | Outperform |
Feb-06-24 | Downgrade | Evercore ISI | Outperform → In-line |
Feb-02-24 | Downgrade | Bernstein | Outperform → Mkt Perform |
Jan-31-24 | Downgrade | Maxim Group | Buy → Hold |
Jan-31-24 | Downgrade | Robert W. Baird | Neutral → Underperform |
Jan-24-24 | Downgrade | Canaccord Genuity | Hold → Sell |
Dec-14-23 | Reiterated | RBC Capital Mkts | Sector Perform |
May-30-23 | Initiated | William Blair | Outperform |
May-04-23 | Resumed | Piper Sandler | Overweight |
Mar-21-23 | Initiated | Bernstein | Outperform |
Jan-18-23 | Initiated | Canaccord Genuity | Hold |
Jan-17-23 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
Dec-19-22 | Downgrade | Jefferies | Buy → Hold |
Jul-13-22 | Initiated | Cantor Fitzgerald | Overweight |
Jun-01-22 | Upgrade | Maxim Group | Hold → Buy |
May-23-22 | Initiated | SVB Leerink | Mkt Perform |
May-06-22 | Downgrade | Robert W. Baird | Outperform → Neutral |
May-03-22 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
Feb-03-22 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
Jan-27-22 | Reiterated | JP Morgan | Overweight |
Jan-27-22 | Reiterated | Morgan Stanley | Underweight |
Jan-27-22 | Reiterated | RBC Capital Mkts | Outperform |
Jan-27-22 | Reiterated | Stifel | Hold |
Jan-27-22 | Reiterated | Wolfe Research | Outperform |
Jan-20-22 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
Dec-09-21 | Initiated | Wells Fargo | Overweight |
Nov-19-21 | Initiated | BMO Capital Markets | Market Perform |
Nov-19-21 | Downgrade | Piper Sandler | Overweight → Neutral |
Sep-09-21 | Downgrade | Stifel | Buy → Hold |
Sep-07-21 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
Jul-20-21 | Downgrade | SVB Leerink | Mkt Perform → Underperform |
Jul-19-21 | Resumed | Wolfe Research | Outperform |
Jul-01-21 | Initiated | Raymond James | Mkt Perform |
Jun-11-21 | Downgrade | Daiwa Securities | Outperform → Neutral |
Feb-23-21 | Upgrade | Robert W. Baird | Neutral → Outperform |
Feb-02-21 | Reiterated | H.C. Wainwright | Buy |
Dec-30-20 | Initiated | Daiwa Securities | Outperform |
Nov-30-20 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
Nov-20-20 | Initiated | Bernstein | Outperform |
Oct-28-20 | Initiated | UBS | Buy |
Jul-31-20 | Reiterated | H.C. Wainwright | Buy |
Jul-08-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
Apr-30-20 | Reiterated | H.C. Wainwright | Buy |
Apr-28-20 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
Mar-04-20 | Initiated | Barclays | Overweight |
Jan-31-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
Nov-19-19 | Upgrade | Guggenheim | Neutral → Buy |
Nov-12-19 | Initiated | SunTrust | Buy |
Oct-17-19 | Resumed | BofA/Merrill | Buy |
Sep-03-19 | Upgrade | Goldman | Neutral → Buy |
Aug-01-19 | Downgrade | Needham | Buy → Hold |
May-23-19 | Resumed | Citigroup | Buy |
May-21-19 | Initiated | Credit Suisse | Outperform |
Apr-12-19 | Initiated | Evercore ISI | In-line |
Mar-26-19 | Upgrade | William Blair | Mkt Perform → Outperform |
Mar-19-19 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
Feb-06-19 | Downgrade | Maxim Group | Buy → Hold |
View All
Vertex Pharmaceuticals, Inc. Stock (VRTX) Latest News
Vertex Pharmaceuticals executive sells over $23k in company stock By Investing.com - Investing.com
Investing.com
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares Sold by Jag Capital Management LLC - MarketBeat
MarketBeat
Vertex Pharmaceuticals Inc. stock underperforms Friday when compared to competitors despite daily gains - MarketWatch
MarketWatch
Vertex Pharmaceuticals executive sells shares worth over $13k - Investing.com UK
Investing.com UK
Vertex Pharmaceuticals executive sells over $23k in company stock - Investing.com UK
Investing.com UK
Vertex Pharmaceuticals Inc. stock outperforms competitors on strong trading day - MarketWatch
MarketWatch
Vertex Pharmaceuticals, Inc. Stock (VRTX) Financials Data
Vertex Pharmaceuticals, Inc. (VRTX) Revenue 2024
VRTX reported a revenue (TTM) of $10.19 billion for the quarter ending March 31, 2024, a +10.61% rise year-over-year.
Vertex Pharmaceuticals, Inc. (VRTX) Net Income 2024
VRTX net income (TTM) was $4.02 billion for the quarter ending March 31, 2024, a +23.31% increase year-over-year.
Vertex Pharmaceuticals, Inc. (VRTX) Cash Flow 2024
VRTX recorded a free cash flow (TTM) of $3.48 billion for the quarter ending March 31, 2024, a -10.57% decrease year-over-year.
Vertex Pharmaceuticals, Inc. (VRTX) Earnings per Share 2024
VRTX earnings per share (TTM) was $15.41 for the quarter ending March 31, 2024, a +22.69% growth year-over-year.
Vertex Pharmaceuticals, Inc. Stock (VRTX) Insider Trading
Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
---|---|---|---|---|---|---|---|
Arbuckle Stuart A | EVP, COO |
May 15 '24 |
Sale |
430.93 |
69 |
29,734 |
49,691 |
ALTSHULER DAVID | EVP, Chief Scientific Officer |
May 15 '24 |
Sale |
430.93 |
54 |
23,270 |
25,813 |
Sachdev Amit | EVP Chief Patient & Ext Af Off |
May 15 '24 |
Sale |
430.93 |
32 |
13,790 |
55,325 |
Bhatia Sangeeta N. | Director |
May 02 '24 |
Sale |
402.95 |
467 |
188,178 |
4,435 |
Ambrose Kristen | SVP & Chief Accounting Officer |
Apr 02 '24 |
Sale |
419.00 |
240 |
100,560 |
7,500 |
Arbuckle Stuart A | EVP, COO |
Feb 26 '24 |
Sale |
425.70 |
5,034 |
2,142,974 |
49,691 |
ALTSHULER DAVID | EVP, Global Research and CSO |
Feb 26 '24 |
Sale |
425.70 |
4,239 |
1,804,542 |
25,813 |
Sachdev Amit | EVP Chief Patient & Ext Af Off |
Feb 26 '24 |
Sale |
425.70 |
3,004 |
1,278,803 |
55,325 |
Ambrose Kristen | SVP & Chief Accounting Officer |
Feb 26 '24 |
Sale |
425.70 |
883 |
375,893 |
7,965 |
Atkinson Edward Morrow III | EVP, Chief Technical Ops. Off. |
Feb 26 '24 |
Sale |
425.70 |
883 |
375,893 |
15,972 |
About Vertex Pharmaceuticals, Inc.
Vertex Pharmaceuticals Incorporated, a biotechnology company, develops medicines for serious diseases. The company focuses on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs. It markets ORKAMBI (lumacaftor in combination with ivacaftor) to treat patients with CF 12 years of age and older who are homozygous for the F508del mutation in their cystic fibrosis transmembrane conductance regulator (CFTR) gene; KALYDECO (ivacaftor) for the treatment of patients with CF who have specific mutations in their CFTR gene, including the G551D mutation; and SYMDEKO (tezacaftor in combination with ivacaftor) to treat patients with CF 12 years of age and older who are F508del homozygous or who have 1 mutation that is responsive to tezacaftor/ivacaftor. The company also develops VX-659 and VX-445, which are CFTR corrector compounds in Phase II clinical trial; VX-150 that is in Phase II clinical trial to treat pain; VX-128, which is in Phase I clinical trial for the treatment of pain; CTX001, an investigational gene editing treatment that is in Phase I/II trial for the treatment of beta-thalassemia and sickle cell disease; pimodivir (JNJ-63623872), which is in a Phase III clinical development program to treat influenza; and VX-210 to treat acute spinal cord injury. It sells its products primarily to specialty pharmacy providers in North America, as well as government-owned and supported customers internationally. The company has collaborations with Cystic Fibrosis Foundation Therapeutics Incorporated; CRISPR Therapeutics AG; Moderna Therapeutics, Inc.; BioAxone Biosciences, Inc.; Parion Sciences, Inc.; Merck KGaA; Janssen Pharmaceuticals, Inc; and Q-State Biosciences, Inc. The company was founded in 1989 and is headquartered in Boston, Massachusetts.
Cap:
|
Volume (24h):